Minerva Neurosciences (NERV)
Develops roluperidone for negative symptoms of schizophrenia through a confirmatory Phase 3 trial.
$3.59
vs last close−0.22 (−5.85%)
Something off on this page? Send us feedback.
Next report
Nov 4, 26
in 42 days
EPS estimate
−$0.14
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.56−$0.50−$0.43−$0.36−$0.64−$2.86−$0.14Pending
Estimate−$1.05−$1.07−$0.95−$0.35−$0.11−$0.13−$0.19−$0.14
Surprise+46.7%+53.3%+54.7%−2.9%−481.8%−2,100.0%+27.6%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$42.2K——————Pending
Estimate————————
Surprise————————
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.12 | — | — |
| Sep 2027 | −$0.12 | — | — |
| Jun 2027 | −$0.19 | — | — |
| Mar 2027 | −$0.18 | — | — |
| Dec 2026 | −$0.16 | — | — |
| Nov 2026 | −$0.14 | — | — |
| Aug 2026 | −$0.19 | −$0.14 | +27.6% |
| May 2026 | −$0.13 | −$2.86 | −2,100.0% |
| Mar 2026 | −$0.11 | −$0.64 | −481.8% |
| Nov 2025 | −$0.35 | −$0.36 | −2.9% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.12 | — | — | $0 | — | — | — |
| Sep 2027 | −$0.12 | — | — | $0 | — | — | — |
| Jun 2027 | −$0.19 | — | — | $0 | — | — | — |
| Mar 2027 | −$0.18 | — | — | $0 | — | — | — |
| Dec 2026 | −$0.16 | — | — | $0 | — | — | — |
| Nov 4, 2026 | −$0.14 | — | — | $0 | — | — | — |
| Aug 7, 2026 | −$0.19 | −$0.14 | +27.6% | — | — | — | −3.8% |
| May 5, 2026 | −$0.13 | −$2.86 | −2,100.0% | — | — | — | −1.3% |
| Mar 11, 2026 | −$0.11 | −$0.64 | −481.8% | — | — | — | −8.1% |
| Nov 5, 2025 | −$0.35 | −$0.36 | −2.9% | — | — | — | +4.1% |
| Aug 14, 2025 | |||||||
| May 13, 2025 | |||||||
| Feb 25, 2025 | |||||||
| Nov 5, 2024 | |||||||
| Aug 6, 2024 | |||||||
| May 1, 2024 | |||||||
| Feb 22, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 1, 2023 | |||||||
| May 15, 2023 | |||||||
| Mar 8, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 9, 2022 | |||||||
| May 4, 2022 | |||||||
| Mar 1, 2022 | |||||||
| Nov 8, 2021 | |||||||
| Aug 2, 2021 | |||||||
| May 12, 2021 | |||||||
| Mar 8, 2021 | |||||||
| Nov 2, 2020 | |||||||
| Aug 3, 2020 | |||||||
| May 4, 2020 | |||||||
| Mar 9, 2020 | |||||||
| Nov 4, 2019 | |||||||
| Aug 5, 2019 | |||||||
| May 6, 2019 | |||||||
| Mar 12, 2019 | |||||||
| Nov 5, 2018 | |||||||
| Aug 2, 2018 | |||||||
| May 3, 2018 | |||||||
| Mar 12, 2018 | |||||||
| Nov 6, 2017 | |||||||
| Aug 3, 2017 | |||||||
| May 4, 2017 | |||||||
| Mar 13, 2017 | |||||||
| Nov 3, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 3, 2016 | |||||||
| Mar 14, 2016 | |||||||
| Nov 5, 2015 | |||||||
| Aug 5, 2015 |